Business Context and Reporting Period
Company: VivoSim Labs, Inc. (VIVS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2026 (Event Date)
Reporting Period: The filing covers the pricing and closing of a best efforts public offering (the "Offering") on March 31, 2026, with the Initial Tranche closing on April 1, 2026.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than standard operating results. Key financial terms include:
- Net Proceeds (Initial Tranche): Approximately $2.5 million (after deducting offering expenses and placement agent fees).
- Securities Issued (Initial Tranche):
- 286,557 shares of Common Stock.
- 2,345,022 Pre-Funded Warrants.
- 3,947,369 accompanying Common Warrants (429,836 attached to Common Stock; 3,517,533 attached to Pre-Funded Warrants).
- Offering Prices:
- Common Stock + Warrants: $1.14 per unit.
- Pre-Funded Warrant + Warrants: $1.139 per unit.
- Warrant Terms:
- Common Warrants Exercise Price: $1.71 per share.
- Placement Agent Warrants Exercise Price: $1.425 per share.
- Expiration: Fifth anniversary of issuance.
- Placement Agent Fees: 7.5% cash fee plus up to 175,439 Placement Agent Warrants (131,579 issued at Initial Tranche closing).
Material Changes and Transaction Structure
The primary material change is the entry into a Material Definitive Agreement to raise capital via a two-tranche structure:
- Initial Tranche: Closed April 1, 2026, generating the $2.5 million in net proceeds noted above.
- Second Tranche (Over-Allotment): An option for purchasers to buy up to an additional $1,000,000 worth of securities on the 30th day following the Initial Tranche Closing.
- Conditions for Second Tranche:
- Stock closing price must be at least $1.43 on the trading day prior to the Second Tranche Closing Date.
- Average daily trading volume must be at least $100,000 for the 10 consecutive trading days prior to the closing.
- Beneficial Ownership Limitation: Purchasers may be required to purchase Pre-Funded Warrants instead of Common Stock if the purchase would result in beneficial ownership exceeding 9.99% (or 4.99% at election) of outstanding shares.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use the net proceeds for working capital and general corporate purposes, specifically including:
- Capital expenditures.
- Research and development expenditures.
- Regulatory affairs expenditures.
- Legal expenditures (including intellectual property protection).
- Acquisitions of new technologies, investments, and business combinations.
Management Commentary: The filing does not provide specific forward-looking financial guidance (e.g., revenue targets) but confirms the strategic intent to fund operations and growth initiatives. The filing includes standard disclaimers that representations in the agreements are for the benefit of the parties and do not constitute factual information regarding the Company's business outside of the transaction terms.
Investor Verification Checklist
- Dilution Impact: Verify the total number of shares outstanding post-closing, including the immediate exercisability of Pre-Funded Warrants and the potential dilution from the 1.5 Common Warrants per share sold.
- Second Tranche Viability: Monitor the stock price and trading volume to determine if the conditions for the $1,000,000 Second Tranche (price ≥ $1.43) are met within 30 days.
- Warrant Exercise Economics: Review the cashless exercise provision for Common Warrants, which could result in the issuance of significantly more shares than the face value if the Black Scholes Value is high relative to the stock price.
- Placement Agent Warrants: Confirm the total number of Placement Agent Warrants issued (131,579 initially) and their exercise price ($1.425) relative to the current market price.
- Registration Statement: Cross-reference the Form S-1 (File No. 333-294716) for detailed risk factors and full terms of the warrants and purchase agreements.